High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: A phase II and pharmacodynamic study

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Mace L. Rothenberg, Malcolm J. Moore, M. Christine Cripps et al. · Annals of Oncology · 1996 · 569 citations · Full text

Medicine, Oncology, Pharmacology +9

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

William D. Kingsbury, Jeffrey C. Boehm, Dalia R. Jakas et al. · Journal of Medicinal Chemistry · 1991 · 516 citations

Medicine, Medicinal Chemistry, Pharmacology +10

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Philippe Rougier, R. Bugat, Jean‐Yves Douillard et al. · Journal of Clinical Oncology · 1997 · 433 citations

Medicine, Oncology, Pharmacology +14

Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

Robert Hertzberg, Mary Jo Caranfa, Kenneth G. Holden et al. · Journal of Medicinal Chemistry · 1989 · 414 citations

Medicine, Medicinal Chemistry, Pharmacology +12

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

Y. Shimada, Makoto Yoshino, A Wakui et al. · Journal of Clinical Oncology · 1993 · 396 citations

Medicine, Oncology, Pharmacology +15